Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740102 | 0.88 | ACP1 (0.41) | ABCG2TRPA1MAPT | |
| SCHEMBL16740240 | 0.87 | BRAF (0.36) | ABCG2ABCB1ABCC1BRAFTRPA1 | |
| SCHEMBL16740183 | 0.86 | KDM4E (0.43) | ABCG2ABCB1ABCC1TSHRTRPA1 | |
| SCHEMBL16740237 | 0.86 | AGPAT2 (0.41) | ABCG2BRAFTRPA1TP53POLB | |
| SCHEMBL16740141 | 0.86 | SLC2A1 (0.42) | ABCG2TRPA1TP53POLBMAPT | |
| SCHEMBL16740076 | 0.85 | ABCG2 (0.34) | ABCG2ABCB1ABCC1TRPA1PIK3CA | |
| SCHEMBL16740095 | 0.84 | ACP1 (0.39) | ABCG2POLBMAPT | |
| SCHEMBL16740103 | 0.84 | TRPA1 (0.41) | ABCG2ABCC1TSHRTRPA1TP53 | |
| SCHEMBL16740389 | 0.84 | ABCG2 (0.42) | ABCG2ABCB1ABCC1TRPA1MAPT | |
| SCHEMBL16739933 | 0.84 | ABCG2 (0.37) | ABCG2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | claimed |
| EP-3071553-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | KCNH2 4821/4885ABCG2 767/4885ABCB1 278/4885 |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | KCNH2 3952/4885ABCG2 4475/4885ABCB1 2939/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | KCNH2 3952/4885ABCG2 4475/4885ABCB1 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.